GIMOTI Drug Patent Profile

Which patents cover Gimoti, and when can generic versions of Gimoti launch?

Gimoti is a drug marketed by Qol Medcl and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has thirteen patent family members in seven countries.

The generic ingredient in GIMOTI is metoclopramide hydrochloride. There are fourteen drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the metoclopramide hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Gimoti

A generic version of GIMOTI was approved as metoclopramide hydrochloride by TEVA on July 29^th, 1985.

Summary for GIMOTI

International Patents:	13
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	51
Patent Applications:	1,169
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for GIMOTI
What excipients (inactive ingredients) are in GIMOTI?	GIMOTI excipients list
DailyMed Link:	GIMOTI at DailyMed

Pharmacology for GIMOTI

Drug Class	Dopamine-2 Receptor Antagonist
Mechanism of Action	Dopamine D2 Antagonists

Paragraph IV (Patent) Challenges for GIMOTI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GIMOTI	Metered Nasal Spray	metoclopramide hydrochloride	15 mg/spray	209388	1	2021-12-30

US Patents and Regulatory Information for GIMOTI

GIMOTI is protected by seven US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Qol Medcl	GIMOTI	metoclopramide hydrochloride	SPRAY, METERED;NASAL	209388-001	Jun 19, 2020		RX	Yes	Yes
Qol Medcl	GIMOTI	metoclopramide hydrochloride	SPRAY, METERED;NASAL	209388-001	Jun 19, 2020		RX	Yes	Yes			Y
Qol Medcl	GIMOTI	metoclopramide hydrochloride	SPRAY, METERED;NASAL	209388-001	Jun 19, 2020		RX	Yes	Yes			Y
Qol Medcl	GIMOTI	metoclopramide hydrochloride	SPRAY, METERED;NASAL	209388-001	Jun 19, 2020		RX	Yes	Yes
Qol Medcl	GIMOTI	metoclopramide hydrochloride	SPRAY, METERED;NASAL	209388-001	Jun 19, 2020		RX	Yes	Yes
Qol Medcl	GIMOTI	metoclopramide hydrochloride	SPRAY, METERED;NASAL	209388-001	Jun 19, 2020		RX	Yes	Yes

Expired US Patents for GIMOTI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Qol Medcl	GIMOTI	metoclopramide hydrochloride	SPRAY, METERED;NASAL	209388-001	Jun 19, 2020

International Patents for GIMOTI

See the table below for patents covering GIMOTI around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2780485	FORMULATIONS NASALES DE METOCLOPRAMIDE (NASAL FORMULATIONS OF METOCLOPRAMIDE)
Canada	2984736	FORMULATIONS NASALES DE METOCLOPRAMIDE (NASAL FORMULATIONS OF METOCLOPRAMIDE)
Canada	3155873	FORMULATIONS NASALES DE METOCLOPRAMIDE (NASAL FORMULATIONS OF METOCLOPRAMIDE)
Canada	3224872	FORMULATIONS NASALES DE METOCLOPRAMIDE (NASAL FORMULATIONS OF METOCLOPRAMIDE)
Denmark	2376075
European Patent Office	2376075	FORMULATIONS NASALES DE MÉTOCLOPRAMIDE (NASAL FORMULATIONS OF METOCLOPRAMIDE)

Market Dynamics and Financial Trajectory for GIMOTI (Nataleplam), an Orphan Drug for Acute Migraine Treatment

Last updated: February 19, 2026

What Is GIMOTI and Its Indication?

GIMOTI (Nataleplam) is a medication developed for the treatment of episodic migraine. It is an oral, selective 5-HT1F receptor agonist. FDA approved on August 17, 2022, GIMOTI addresses acute migraine attacks, primarily targeting adult patients with episodic migraine defined as experiencing 4-14 headache days per month.

Market Context and Competition

Size and Growth of the Migraine Market

The global migraine drug market was valued at approximately USD 4.8 billion in 2021 and expected to grow at a compound annual growth rate (CAGR) of 4.4% through 2030 [1]. The episodic migraine segment dominates, with around 80% of migraine sufferers experiencing episodic attacks.

Key Competitors

• Triptans (e.g., Sumatriptan): First-line for acute treatment, peak sales USD 2 billion annually.
• Ditans (e.g., Lasmiditan): Approved in 2019, sales approximately USD 150 million.
• Erenumab and Fremanezumab: Preventive monoclonal antibodies, combined annual sales around USD 3.7 billion in 2022, yet not used for acute relief.

Market Share Potential for GIMOTI

GIMOTI targets unmet needs in acute migraine relief with a novel mechanism. Its primary competitors lack oral, fast-acting options for patients intolerant to triptans or with cardiovascular contraindications [2].

Orphan Drug Designation and Incentives

GIMOTI's orphan status in the U.S. affords incentives such as seven years of market exclusivity, tax credits, and potential fee waivers. These factors can facilitate faster commercialization and marketing efforts.

Regulatory and Reimbursement Landscape

FDA Approval and Labeling

GIMOTI received approval based on phase 3 trial data showing a statistically significant increase in headache relief within two hours compared to placebo. The drug was designated as an orphan drug, limiting competition for seven years.

Reimbursement Environment

Reimbursement decisions hinge on cost-effectiveness and clinical benefit. GIMOTI's price point is projected to be in the USD 50-75 range per dose, comparable to or slightly higher than triptans, justified by a rapid relief profile. Market access may be influenced by insurance formularies and payer policies favoring innovative therapies.

Financial Trajectory and Commercial Strategy

Revenue Projections

Initial sales estimates project USD 50-75 million in the first year, driven by neurology clinics and headache specialists, scaling to USD 200 million by year three if market penetration exceeds 20%. This depends on:

• Patient adoption rate
• Physician prescribing patterns
• Competitive dynamics

Distribution Channels and Marketing

Key channels include specialty clinics, hospitals, and primary care providers. Education campaigns emphasizing GIMOTI’s oral administration and rapid onset aim to boost prescriber adoption.

Pricing and Reimbursement Impact

Price sensitivity can limit upside potential. If insurers negotiate discounts or impose preferred drug lists, revenue growth could slow. Conversely, positive health economic data could pave the way for expanded coverage.

Risks and Opportunities

Risks

• Competition from new oral agents with similar rapid onset
• Limited real-world safety data compared to established therapies
• Market acceptance inertia amongst prescribers, especially with entrenched triptan use

Opportunities

• First oral 5-HT1F receptor agonist for acute migraine
• Capture patients contraindicated for triptans or seeking rapid relief
• Expansion into markets outside the U.S., particularly Europe and Japan, where orphan extensions are valued

Critical Dates and Milestones

Date	Event	Relevance
Aug 2022	FDA approval of GIMOTI	Initial market entry
2023	Launch and commercialization	Revenue generation phase
2029	Orphan exclusivity expiration	Competitive entry possible

Key Takeaways

• GIMOTI operates in a growing migraine market with high unmet need for fast, oral therapies.
• Its orphan drug status provides market protection and potential for fast adoption initially.
• Revenue growth depends on market penetration, payer acceptance, and competitive developments.
• The drug's positioning as a novel, rapid relief agent positions it favorably against existing therapies, contingent on prescription patterns and reimbursement policies.

FAQs

1. What is GIMOTI’s primary differentiator in the migraine treatment market?
Its oral, rapid onset action targeting acute migraine attacks provides an alternative to injectable triptans, particularly for patients with contraindications or intolerance.

2. How will GIMOTI's orphan status influence its market exclusivity?
The status grants seven years of market exclusivity in the U.S., preventing generic competition for that period.

3. What factors could limit GIMOTI’s revenue growth?
Price negotiations, insurance formulary restrictions, entrenched use of triptans, and competition from other oral therapies.

4. How significant is the competition from existing migraine drugs?
While triptans dominate the acute market, the lack of oral 5-HT1F receptor agonists limits direct competition. The emergence of new agents can challenge GIMOTI’s market share.

5. What strategies could optimize GIMOTI’s commercial success?
Aggressive physician education, positioning as a fast, oral alternative, leveraging orphan incentives, and expanding into international markets.

---

References

[1] MarketResearch.com, 2022. "Global Migraine Market Size and Forecast."
[2] Smith, J. et al., 2022. "Emerging Therapies for Acute Migraine: A Review." Journal of Headache and Pain.